MoonLake Immunotherapeutics submits BLA to FDA for sonelokimab

MoonLake Immunotherapeutics has submitted a Biologics License Application to the U.S. Food and Drug Administration seeking approval of sonelokimab for the treatment of moderate-to-severe hidradenitis suppurativa in adults and patients aged 12 and older.